Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

To "B" (CD20) or not to "B".

Duque RE.

Cytometry. 1994 Mar 15;18(1):62. No abstract available.

2.

B cell number and function in Graves' disease.

Wilson R, Pearson C, McKillop JH, Thomson JA.

Autoimmunity. 1994;17(3):251. No abstract available.

PMID:
7524703
3.

Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.

Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, Treter S, Harper D, Kitamura H, Vitetta ES, Abraham S, Awwad M, White-Scharf ME, Sachs DH, Thall A, Cooper DK.

Xenotransplantation. 2001 Aug;8(3):157-71.

PMID:
11472623
4.

Soluble molecules in lymphoproliferative disorders.

Vinante F, Morosato L, De Sabata D, Pizzolo G.

Leukemia. 1991;5 Suppl 1:18-21. Review. No abstract available.

PMID:
1653881
5.

Immunologic monitoring after organ transplantation: relationship between Epstein-Barr virus infection and CD19+ B cells measured by flow cytometry.

Morrissey PE, Lorber KM, Marcarelli M, Bia MJ, Kliger AS, Lorber MI.

Transplant Proc. 1995 Feb;27(1):1428-30. No abstract available.

PMID:
7533384
6.

[Quantitative flowcytometric analysis of B cell surface antigens in patients with autoimmune diseases].

Oooto Y, Ikemoto T, Nakagawa T, Shimizu A.

Rinsho Byori. 1995 Apr;43(4):381-4. Japanese.

PMID:
7537832
7.

CD20+ T-cell lymphoma. Neoplastic transformation of a normal T-cell subset.

Quintanilla-Martinez L, Preffer F, Rubin D, Ferry JA, Harris NL.

Am J Clin Pathol. 1994 Oct;102(4):483-9.

8.

Low level CD20 expression on T cell malignancies.

Warzynski MJ, Graham DM, Axtell RA, Zakem MH, Rotman RK.

Cytometry. 1994 Jun 15;18(2):88-92.

9.

CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes.

Hultin LE, Hausner MA, Hultin PM, Giorgi JV.

Cytometry. 1993;14(2):196-204.

10.

Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.

Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3304s-3314s.

PMID:
10541379
11.

CD 5/20 positive cell numbers in patients with a history of miscarriage.

Wilson R, Maclean MA, Cumming GP, Pearson C, Walker JJ.

Autoimmunity. 1993;15(1):91. No abstract available.

PMID:
7692994
12.
13.
14.

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R.

Blood. 1994 Oct 15;84(8):2457-66.

15.

Expression of lymphocytes Fc epsilon RII/CD23 in allergic children undergoing hyposensitization.

Gagro A, Rabatić S, Tresćec A, Dekaris D, Medar-Lasić M.

Int Arch Allergy Immunol. 1993;101(2):203-8.

PMID:
7685220
16.
17.
18.

Low expression of CD20 and CD23 in Epstein-Barr virus-induced B cell tumors in SCID/hu mice.

Garnier JL, Cooper NR, Cannon MJ.

Am J Pathol. 1993 Feb;142(2):353-8.

19.

Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.

Hooijberg E, van den Berk PC, Sein JJ, Wijdenes J, Hart AA, de Boer RW, Melief CJ, Hekman A.

Cancer Res. 1995 Feb 15;55(4):840-6.

20.

Usefulness of CD79b expression in the diagnosis of B-cell chronic lymphoproliferative disorders.

McCarron KF, Hammel JP, Hsi ED.

Am J Clin Pathol. 2000 Jun;113(6):805-13. Erratum in: Am J Clin Pathol 2000 Sep;114(3):489.

Items per page

Supplemental Content

Support Center